2002: February: Alzheimer’s Research Papers
Heo HJ, Hong SC, Cho HY, Hong B, Kim HK, Kim EK, Shin DH. Inhibitory effect of zeatin, isolated from Fiatoua villosa, on acetylcholinesterase activity from PC12 cells. Mol Cells. 2002 Feb 28;13(1):113-7.
Emons G, Westphalen S. [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated] MMW Fortschr Med. 2002 Feb 28;144(9):30-3.
Verlinsky Y, Rechitsky S, Verlinsky O, Masciangelo C, Lederer K, Kuliev A. Preimplantation diagnosis for early-onset Alzheimer disease caused by V717L mutation. JAMA. 2002 Feb 27;287(8):1018-21.
Towner D, Loewy RS. Ethics of preimplantation diagnosis for a woman destined to develop early-onset Alzheimer disease. JAMA. 2002 Feb 27;287(8):1038-40.
Jellinger K. Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology. 2002 Feb 26;58(4):671-2; discussion 671-2.
Weidemann A, Eggert S, Reinhard FB, Vogel M, Paliga K, Baier G, Masters CL, Beyreuther K, Evin G. A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry. 2002 Feb 26;41(8):2825-35.
Kakimura JI, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Microglial activation and amyloid-b clearance induced by exogenous heat-shock proteins. FASEB J. 2002 Feb 25;
Gottlieb S. Higher folic acid levels could reduce risk of Alzheimer's disease. BMJ. 2002 Feb 23;324(7335):441A.
Ji SR, Wu Y, Sui SF. Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. J Biol Chem. 2002 Feb 22;277(8):6273-9.
Hof PR, Duan H, Page TL, Einstein M, Wicinski B, He Y, Erwin JM, Morrison JH. Age-related changes in GluR2 and NMDAR1 glutamate receptor subunit protein immunoreactivity in corticocortically projecting neurons in macaque and patas monkeys. Brain Res. 2002 Feb 22;928(1-2):175-86.
Nathan BP, Jiang Y, Wong GK, Shen F, Brewer GJ, Struble RG. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res. 2002 Feb 22;928(1-2):96-105.
Arsland D. [Dementia with Lewy bodies] Tidsskr Nor Laegeforen. 2002 Feb 20;122(5):525-9.
Engedal K. [Diagnosis and treatment of dementia] Tidsskr Nor Laegeforen. 2002 Feb 20;122(5):520-4.
Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins
Sun YX, Wright HT, Janciauskiene S. Alpha1-antichymotrypsin/Alzheimer's peptide Abeta(1-42) complex perturbs lipid metabolism and activates transcription factors PPARgamma and NFkappaB in human neuroblastoma (Kelly) cells. J Neurosci Res. 2002 Feb 15;67(4):511-22.
Mathews PM, Guerra CB, Jiang Y, Grbovic OM, Kao BH, Schmidt SD, Dinakar R, Mercken M, Hille-Rehfeld A, Rohrer J, Mehta P, Cataldo AM, Nixon RA. Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J Biol Chem. 2002 Feb 15;277(7):5299-307.
Del Rio MJ, Velez-Pardo C. Monoamine neurotoxins-induced apoptosis in lymphocytes by a common oxidative stress mechanism: involvement of hydrogen peroxide (H(2)O(2)), caspase-3, and nuclear factor kappa-B (NF-kappaB), p53, c-Jun transcription factors. Biochem Pharmacol. 2002 Feb 15;63(4):677-88.
Praticò D. Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol. 2002 Feb 15;63(4):563-7.
Volkow ND, Zhu W, Felder CA, Mueller K, Welsh TF, Wang GJ, de Leon MJ. Changes in brain functional homogeneity in subjects with Alzheimer's disease. Psychiatry Res. 2002 Feb 15;114(1):39-50.
Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res. 2002 Feb 15;67(4):494-500.
Hampel H, Teipel SJ, Bayer W, Alexander GE, Schwarz R, Schapiro MB, Rapoport SI, Möller HJ. Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. J Neurol Sci. 2002 Feb 15;194(1):15-9.
Kiuchi Y, Isobe Y, Fukushima K. Type IV collagen prevents amyloid beta-protein fibril formation. Life Sci. 2002 Feb 15;70(13):1555-64.
Jonnala RR, Terry AV, Buccafusco JJ. Nicotine increases the expression of high affinity nerve growth factor receptors in both in vitro and in vivo. Life Sci. 2002 Feb 15;70(13):1543-54.
Izawa I, Nishizawa M, Ohtakara K, Inagaki M. Densin-180 interacts with delta-catenin/neural plakophilin-related armadillo repeat protein at synapses. J Biol Chem. 2002 Feb 15;277(7):5345-50.
Ki CS, Na DL, Kim DK, Kim HJ, Kim JW. Genetic association of an apolipoprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer's disease. Neurosci Lett. 2002 Feb 15;319(2):75-8. ,
Capell A, Meyn L, Fluhrer R, Teplow DB, Walter J, Haass C. Apical sorting of beta-secretase limits amyloid beta-peptide production. J Biol Chem. 2002 Feb 15;277(7):5637-43.
Grüninger-Leitch F, Schlatter D, Küng E, Nelböck P, Döbeli H. Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem. 2002 Feb 15;277(7):4687-93.
Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, Szweda LI, Kaminski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem. 2002 Feb 15;277(7):4644-8.
Hu Q, Cool BH, Wang B, Hearn MG, Martin GM. A candidate molecular mechanism for the association of an intronic polymorphism of FE65 with resistance to very late onset dementia of the Alzheimer type. Hum Mol Genet. 2002 Feb 15;11(4):465-75.
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002 Feb 14;346(7):476-83. ,
Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Merkle RK, Gong CX. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett. 2002 Feb 13;512(1-3):101-6.
Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 2002 Feb 11;12(3):295-8.
Morton RA, Kuenzi FM, Fitzjohn SM, Rosahl TW, Smith D, Zheng H, Shearman M, Collingridge GL, Seabrook GR. Impairment in hippocampal long-term potentiation in mice under-expressing the Alzheimer's disease related gene presenilin-1. Neurosci Lett. 2002 Feb 8;319(1):37-40.
Ylera F, Lurz R, Erdmann VA, Fürste JP. Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1583-8.
Hanyu H, Tanaka Y, Sakurai H, Takasaki M, Abe K. Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease. Neurosci Lett. 2002 Feb 8;319(1):33-6.
Koistinaho M, Kettunen MI, Goldsteins G, Keinänen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen RA, Higgins LS, Koistinaho J. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1610-5.
O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1485-90.
Papasozomenos SCh, Shanavas A. Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1140-5.
Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002 Feb 4;156(3):519-29.
Mufson EJ, Ma SY, Dills J, Cochran EJ, Leurgans S, Wuu J, Bennett DA, Jaffar S, Gilmor ML, Levey AI, Kordower JH. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002 Feb 4;443(2):136-53.
Holmes C, Lovestone S. The clinical phenotype of familial and sporadic late onset Alzheimer's disease. Int J Geriatr Psychiatry. 2002 Feb;17(2):146-9.
Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab. 2002 Feb;22(2):223-31.
Brown VM, Ossadtchi A, Khan AH, Cherry SR, Leahy RM, Smith DJ. High-throughput imaging of brain gene expression. Genome Res. 2002 Feb;12(2):244-54.
Wanker EE. Hip1 and Hippi participate in a novel cell death-signaling pathway. Dev Cell. 2002 Feb;2(2):126-8.
Seo H, Ferree AW, Isacson O. Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. Eur J Neurosci. 2002 Feb;15(3):498-506.
Haring HP. Cognitive impairment after stroke. Curr Opin Neurol. 2002 Feb;15(1):79-84.
Wilcock GK, Birks J, Whitehead A, Evans SJ. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry. 2002 Feb;17(2):175-83.
Sun MK, Alkon DL. Carbonic anhydrase gating of attention: memory therapy and enhancement. Trends Pharmacol Sci. 2002 Feb;23(2):83-9.
Morris JC. Challenging assumptions about Alzheimer's disease: mild cognitive impairment and the cholinergic hypothesis. Ann Neurol. 2002 Feb;51(2):143-4.
Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol. 2002 Feb;173(2):183-95.
Lin WR, Wozniak MA, Wilcock GK, Itzhaki RF. Cytomegalovirus is present in a very high proportion of brains from vascular dementia patients. Neurobiol Dis. 2002 Feb 1;9(1):82-7.
Queralt R, Ezquerra M, Lleó A, Castellví M, Gelpí J, Ferrer I, Acarín N, Pasarín L, Blesa R, Oliva R. A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances. J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):266-9.
Van Ess PJ, Pedersen WA, Culmsee C, Mattson MP, Blouin RA. Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurochem. 2002 Feb;80(4):571-8.
Gau JT, Steinhilb ML, Kao TC, D'Amato CJ, Gaut JR, Frey KA, Turner RS. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol. 2002 Feb 1;160(2):731-8.
Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, Small GW, Chodosh J, Czernin J, Phelps ME. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002 Feb;43(2):253-66.
Figueroa DJ, Morris JA, Ma L, Kandpal G, Chen E, Li YM, Austin CP. Presenilin-dependent gamma-secretase activity modulates neurite outgrowth. Neurobiol Dis. 2002 Feb;9(1):49-60.
Martin BK, Meinert CL, Breitner JC, the ADAPT Research Group . Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials. 2002 Feb;23(1):93-9.
Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 2002 Feb;25(2):79-84.
Thomas VS, Vandenberg EV, Potter JF. Non-neurological factors are implicated in impairments in gait and mobility among patients in a clinical dementia referral population. Int J Geriatr Psychiatry. 2002 Feb;17(2):128-33.
Nishimura I, Uetsuki T, Kuwako K, Hara T, Kawakami T, Aimoto S, Yoshikawa K. Cell death induced by a caspase-cleaved transmembrane fragment of the Alzheimer amyloid precursor protein. Cell Death Differ. 2002 Feb;9(2):199-208.
Teipel SJ, Bayer W, Alexander GE, Zebuhr Y, Teichberg D, Kulic L, Schapiro MB, Möller HJ, Rapoport SI, Hampel H. Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol. 2002 Feb;59(2):243-8.
Cohen GD. Alzheimer's disease. Managing behavioral problems in patients with progressive dementia. Geriatrics. 2002 Feb;57(2):53-4.
Locatelli S, Lütjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol. 2002 Feb 1;59(2):213-6.
Lee JM, Petrucelli L, Fisher G, Ramdath S, Castillo J, Di Fiore MM, D'Aniello A. Evidence for D-aspartyl-beta-amyloid secretase activity in human brain. J Neuropathol Exp Neurol. 2002 Feb;61(2):125-31.
Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol (Berl). 2002 Feb;103(2):91-9.
Borghi R, Pellegrini L, Lacaná E, Diaspro A, Pronzato MA, Vitali A, Roncarati R, Strocchi P, Zaccheo D, D'Adamio L, Tabaton M. Neuronal apoptosis is accompanied by amyloid beta-protein accumulation in the endoplasmic reticulum. J Alzheimers Dis. 2002 Feb;4(1):31-7.
Bassett CN, Swift LL, Montine KS
Zatta P, Zambenedetti P, Stella MP, Licastro F. Astrocytosis, microgliosis, metallothionein-I-II and amyloid expression in high cholesterol-fed rabbits. J Alzheimers Dis. 2002 Feb;4(1):1-9.
Hernández F, Lim F, Lucas JJ, Pérez-Martín C, Moreno F, Avila J. Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):51-8.
Camps P, Muñoz-Torrero D. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25.
Larner AJ. Alzheimer's disease: targets for drug development. Mini Rev Med Chem. 2002 Feb;2(1):1-9.
Solomon B. Towards Alzheimer's disease vaccination. Mini Rev Med Chem. 2002 Feb;2(1):85-92.
Albert SM, Tabert MH, Dienstag A, Pelton G, Devanand e . The impact of mild cognitive impairment on functional abilities in the elderly. Curr Psychiatry Rep. 2002 Feb;4(1):64-8.
Spielman L, Winger D, Ho L, Aisen PS, Shohami E, Pasinetti GM. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol (Berl). 2002 Feb;103(2):157-62.
García-Jiménez A, Cowburn RF, Ohm TG, Lasn H, Winblad B, Bogdanovic N, Fastbom J. Loss of stimulatory effect of guanosine triphosphate on [(35)S]GTPgammaS binding correlates with Alzheimer's disease neurofibrillary pathology in entorhinal cortex and CA1 hippocampal subfield. J Neurosci Res. 2002 Feb 1;67(3):388-98.
Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002 Feb 1;59(2):223-7.
Mustazza C, Borioni A, Del Giudice MR, Gatta F, Ferretti R, Meneguz A, Volpe MT
Lane HY, Chang YC, Su MH, Chiu CC, Huang MC, Chang WH. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. J Clin Psychopharmacol. 2002 Feb;22(1):4-10.
Rocca P, Cocuzza E, Marchiaro L, Bogetto F. Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):369-73.
Yokoyama K, Ikebe S, Komatsuzaki Y, Takanashi M, Mori H, Mochizuki H, Mizuno Y. [A 68-year-old woman with dementia and parkinsonism] No To Shinkei. 2002 Feb;54(2):175-84.
Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002 Feb;2(2):181-97.
Hashimoto Y, Ito Y, Arakawa E, Kita Y, Terashita K, Niikura T, Nishimoto I. Neurotoxic mechanisms triggered by Alzheimer's disease-linked mutant M146L presenilin 1: involvement of NO synthase via a novel pertussis toxin target. J Neurochem. 2002 Feb;80(3):426-37.
Tarkka IM, Lehtovirta M, Soininen H, Pääkkönen A, Karhu J, Partanen J. Auditory adaptation is differentially impaired in familial and sporadic Alzheimer's disease. Biomed Pharmacother. 2002 Feb;56(1):45-9.
Hashimoto K, Iyo M. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs] Nihon Shinkei Seishin Yakurigaku Zasshi. 2002 Feb;22(1):3-13.
Narita K, Murata T, Ito T, Murata I, Fukutani Y, Tsuji Y, Wada Y. A case of diffuse neurofibrillary tangles with calcification. Psychiatry Clin Neurosci. 2002 Feb;56(1):117-20.
Yamada T, Kadekaru H, Matsumoto S, Inada H, Tanabe M, Moriguchi EH, Moriguchi Y, Ishikawa P, Ishikawa AG, Taira K, Yamori Y. Prevalence of dementia in the older Japanese-Brazilian population. Psychiatry Clin Neurosci. 2002 Feb;56(1):71-5.
Ueda H, Kitabayashi Y, Narumoto J, Nakamura K, Kita H, Kishikawa Y, Fukui K. Relationship between clock drawing test performance and regional cerebral blood flow in Alzheimer's disease: a single photon emission computed tomography study. Psychiatry Clin Neurosci. 2002 Feb;56(1):25-9.
Collie A, Maruff P. An analysis of systems of classifying mild cognitive impairment in older people. Aust N Z J Psychiatry. 2002 Feb;36(1):133-40.
Nakagami Y, Oda T. Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. Jpn J Pharmacol. 2002 Feb;88(2):223-6.
Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol. 2002 Feb;88(2):133-8.
Guérin F, Belleville S, Ska B. Characterization of visuoconstructional disabilities in patients with probable dementia of Alzheimer's type. J Clin Exp Neuropsychol. 2002 Feb;24(1):1-17.
Schmitz A, Tikkanen R, Kirfel G, Herzog V. The biological role of the Alzheimer amyloid precursor protein in epithelial cells. Histochem Cell Biol. 2002 Feb 1;117(2):171-80.
Blobel CP. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm Res. 2002 Feb;51(2):83-4.
Wang L, Zhu M, Li X, Gui Q. [The application of Gallyas-Braak stainings in pathologic diagnosis of neurodegenerative diseases] Zhonghua Nei Ke Za Zhi. 2002 Feb;41(2):120-3.
Richarz AN, Brätter P. Speciation analysis of trace elements in the brains of individuals with Alzheimer's disease with special emphasis on metallothioneins. Anal Bioanal Chem. 2002 Feb;372(3):412-7.
Frey J. Bovine spongiform encephalopathy: are the cows mad or full of carbohydrates? Clin Chem Lab Med. 2002 Feb;40(2):101-3.
Katona G, Berglund GI, Hajdu J, Gráf L, Szilágyi L. Crystal structure reveals basis for the inhibitor resistance of human brain trypsin. J Mol Biol. 2002 Feb 1;315(5):1209-18.
Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, Han LY, Bienias JL, Lee VM, Trojanowski JQ, Bennett DA, Arnold SE. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol. 2002 Feb;51(2):182-9. ,
Das UN. Estrogen, statins, and polyunsaturated fatty acids: similarities in their actions and benefits-is there a common link? Nutrition. 2002 Feb;18(2):178-88.
Reese D. Alternatives for Alzheimer's. Three basic approaches offer help and hope. Contemp Longterm Care. 2002 Feb;25(2):8-9.
Maki M, Matsukawa N, Yuasa H, Otsuka Y, Yamamoto T, Akatsu H, Okamoto T, Ueda R, Ojika K. Decreased expression of hippocampal cholinergic neurostimulating peptide precursor protein mRNA in the hippocampus in Alzheimer disease. J Neuropathol Exp Neurol. 2002 Feb;61(2):176-85.
King DL, Arendash GW. Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res. 2002 Feb 1;926(1-2):58-68.
Veinbergs I, Everson A, Sagara Y, Masliah E. Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J Neurosci Res. 2002 Feb 1;67(3):379-87.
Lleó A, Castellví M, Blesa R, Oliva R. Uncommon polymorphism in the presenilin genes in human familial Alzheimer's disease: not to be mistaken with a pathogenic mutation. Neurosci Lett. 2002 Feb 1;318(3):166-8.
Lovestone S, McLoughlin DM. Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):152-61.
Holmes C. Genotype and phenotype in Alzheimer's disease. Br J Psychiatry. 2002 Feb;180:131-4.
Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, Normark S, Hultgren SJ. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science. 2002 Feb 1;295(5556):851-5.
Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis. 2002 Feb 1;9(1):61-8.
Liu L, Ikonen S, Heikkinen T, Tapiola T, van Groen T, Tanila H. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice. Exp Neurol. 2002 Feb;173(2):196-204.
Rachon D, Mysliwska J, Suchecka-Rachon K, Wieckiewicz J, Mysliwski A. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol. 2002 Feb;172(2):387-95.
Jacquemont ML, Campion D, Hahn V, Tallaksen C, Frebourg T, Brice A, Durr A. Spastic paraparesis and atypical dementia caused by PSEN1 mutation (P264L), responsible for Alzheimer's disease. J Med Genet. 2002 Feb;39(2):E2.
Stewart R. Vascular dementia: a diagnosis running out of time. Br J Psychiatry. 2002 Feb;180:152-6.
Rösler M, Frey U.
Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J. 2002 Feb;43(1):28-32.
Copani A, Sortino MA, Nicoletti F, Giuffrida SA. Alzheimer's disease research enters a "new cycle": how significant? Neurochem Res. 2002 Feb;27(1-2):173-6.
Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis. 2002 Feb;9(1):11-23.
Marksteiner J, Kaufmann WA, Gurka P, Humpel C. Synaptic proteins in Alzheimer's disease. J Mol Neurosci. 2002 Feb-Apr;18(1-2):53-63.
Midlöv P, Bondesson A, Eriksson T, Petersson J, Minthon L, Höglund P. Descriptive study and pharmacotherapeutic intervention in patients with epilepsy or Parkinson's disease at nursing homes in southern Sweden. Eur J Clin Pharmacol. 2002 Feb;57(12):903-10.
Hengeveld AF, de Kok A. Structural basis of the dysfunctioning of human 2-oxo Acid dehydrogenase complexes. Curr Med Chem. 2002 Feb;9(4):499-520.
Treuting PM, Hopkins HC, Ware CA, Rabinovitch PR, Ladiges WC. Generation of genetically altered mouse models for aging studies. Exp Mol Pathol. 2002 Feb;72(1):49-55.
Trojanowski JQ. Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery. Am J Pathol. 2002 Feb;160(2):409-11.
Ujiie M, Dickstein DL, Jefferies WA. p97 as a biomarker for Alzheimer disease. Front Biosci. 2002 Feb 1;7:e42-7.
Dringenberg HC, Diavolitsis P. Electroencephalographic activation by fluoxetine in rats: role of 5-HT(1A) receptors and enhancement of concurrent acetylcholinesterase inhibitor treatment. Neuropharmacology. 2002 Feb;42(2):154-61.
McKeith IG. Dementia with Lewy bodies. Br J Psychiatry. 2002 Feb;180:144-7.
Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002 Feb;9(1):88-93.
Marin DB, Sewell MC, Schlechter A. Alzheimer's disease. Accurate and early diagnosis in the primary care setting. Geriatrics. 2002 Feb;57(2):36-40; quiz 43.
Turner MA, Moran NF, Kopelman MD. Subcortical dementia. Br J Psychiatry. 2002 Feb;180:148-51.
Bullock R. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry. 2002 Feb;180:135-9.
Scott HL, Pow DV, Tannenberg AE, Dodd PR. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J Neurosci. 2002 Feb 1;22(3):RC206.
Davis KL, Price CC, Kaplan E, Libon DJ. Error Analysis of the Nine-Word California Verbal Learning Test (CVLT-9) Among Older Adults With and Without Dementia. Clin Neuropsychol. 2002 Feb;16(1):81-9.
Timmons S, Sweeney B, Hyland M, O'Mahony D, Twomey C. New onset seizures in the elderly: aetiology and prognosis. Ir Med J. 2002 Feb;95(2):47-9.
Cerhan JH, Ivnik RJ, Smith GE, Tangalos EC, Petersen RC, Boeve BF. Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease. Clin Neuropsychol. 2002 Feb;16(1):35-42.
Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, Padovani A, Di Luca M. [alpha]-Secretase ADAM10 as Well as [alpha]APPs Is Reduced in Platelets and CSF of Alzheimer Disease Patients. Mol Med. 2002 Feb;8(2):67-74.
Santacruz KS, Tasaki CS, Kim RC, Cotman CW. Brainstem and cortical Lewy bodies in patients presenting clinically with Alzheimer's disease. J Alzheimers Dis. 2002 Feb;4(1):11-7.
Cacabelos R. Pharmacogenomics in Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):59-84.
Castro A, Conde S, Rodriguez-Franco MI, Martinez A. Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):37-50.
Idiaquez J, Sandoval E, Seguel A. Association between neuropsychiatric and autonomic dysfunction in Alzheimer's disease. Clin Auton Res. 2002 Feb;12(1):43-6.
Ikehara S. Bone marrow transplantation: a new strategy for intractable diseases. Drugs Today (Barc). 2002 Feb;38(2):103-11.
Bozyczko-Coyne D, Saporito MS, Hudkins RL. Targeting the JNK pathway for therapeutic benefit in CNS disease. Curr Drug Target CNS Neurol Disord. 2002 Feb;1(1):31-49.
Helmes E, Østbye T. Beyond memory impairment: cognitive changes in Alzheimer's disease. Arch Clin Neuropsychol. 2002 Feb;17(2):179-93.
Vespa A, Gori G, Spazzafumo L. Evaluation of non-pharmacological intervention on antisocial behavior in patients suffering from Alzheimer's disease in a day care center. Arch Gerontol Geriatr. 2002 Feb;34(1):1-8.
Jhamandas JH, Harris KH, MacTavish D, Jassar BS. Novel excitatory actions of galanin on rat cholinergic basal forebrain neurons: implications for its role in Alzheimer's disease. J Neurophysiol. 2002 Feb;87(2):696-704.
DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002 Feb;51(2):145-55.
Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, Matsui M. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol. 2002 Feb;51(2):209-14.
Torreilles F, Touchon J. Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease. Prog Neurobiol. 2002 Feb;66(3):191-203.
Ewbank DC. Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol. 2002 Feb;22(2):146-55.
Sommer B. Alzheimer's disease and the amyloid cascade hypothesis: ten years on. Curr Opin Pharmacol. 2002 Feb;2(1):87-92.
Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002 Feb;440(2):111-22.
Probst A, Tolnay M. [Argyrophilic grain disease (AgD), a frequent and largely underestimated cause of dementia in old patients] Rev Neurol (Paris). 2002 Feb;158(2):155-65.
García-Jiménez A, Cowburn RF, Ohm TG, Lasn H, Winblad B, Bogdanovic N, Fastbom J. Loss of stimulatory effect of guanosine triphosphate on [35S]GTPgammaS binding correlates with Alzheimer's disease neurofibrillary pathology in entorhinal cortex and CA1 hippocampal subfield. J Neurosci Res. 2002 Feb 1;67(3):388-398.
Willems S, Adam S, Van der Linden M. Normal mere exposure effect with impaired recognition in Alzheimer's disease. Cortex. 2002 Feb;38(1):77-86.
Yao J, Li H, Zhang Z. [A case-control study on family history of Alzheimer's disease] Zhonghua Liu Xing Bing Xue Za Zhi. 2002 Feb;23(1):54-6.
Gareri P, De Fazio P, De Sarro G. Neuropharmacology of depression in aging and age-related diseases. Ageing Res Rev. 2002 Feb;1(1):113-34.
Mattson MP, Kruman II, Duan W. Folic acid and homocysteine in age-related disease. Ageing Res Rev. 2002 Feb;1(1):95-111.
L pez Pousa S, Garre Olmo J, Tur n Estrada A, Fajardo Tibau C, Puig Puig O, Lozano Gallego M, Hern ndez Ferr ndiz M, Vilalta Franch J. [The clinical incidence of frontal dementia] Rev Neurol. 2002 Feb 1;34(3):216-22.
Ferenci P, Zollner G, Trauner M. Hepatic transport systems. J Gastroenterol Hepatol. 2002 Feb;17 Suppl 1:105-112.
Fernández-Ruiz J, Lastres-Becker I, Cabranes A, González S, Ramos JA. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb;66(2-3):257-67.
Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev. 2002 Feb 1;1(1):61-77.
Wei Q, Holzer M, Brueckner MK, Liu Y, Arendt T. Dephosphorylation of tau protein by calcineurin triturated into neural living cells. Cell Mol Neurobiol. 2002 Feb;22(1):13-24.
Scheinfeld MH, Roncarati R, Vito P, Lopez PA, Abdallah M, D'Adamio L. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP). J Biol Chem. 2002 Feb 1;277(5):3767-75. ,
Noonan CW, Reif JS, Yost M, Touchstone J. Occupational exposure to magnetic fields in case-referent studies of neurodegenerative diseases. Scand J Work Environ Health. 2002 Feb;28(1):42-8.
Liu SJ, Wang JZ. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin. 2002 Feb;23(2):183-7.
No comments:
Post a Comment